Investors / Media

Infinity Pharmaceuticals, Inc. is an innovative biopharmaceutical company dedicated to discovering, developing and delivering best-in-class medicines to people with difficult-to-treat diseases. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways.

Stock Chart

More »
Stock chart for: INFI.O.  Currently trading at $0.98 with a 52 week high of $3.84 and a 52 week low of $0.84.

Recent Events

View all events »
Q2 2017 Infinity Pharmaceuticals, Inc. Earnings Conference Call
Aug 03, 2017 4:30 p.m. ET
Infinity Pharmaceuticals, Inc. at Precision Lung Cancer Conference
Jul 25, 2017 10:00 a.m. ET
Infinity Pharmaceuticals, Inc. at 2017 Biotechnology Innovation Organization (BIO) International Convention
Jun 22, 2017 1:00 p.m. PT

Recent Releases

More >>
Infinity Provides Company Update and Reports Second Quarter 2017 Financial Results
Aug 03, 2017
- Phase 1 Clinical Study Evaluating IPI-549 as a Monotherapy and in Combination with Opdivo® Advancing - - IPI-549 Monotherapy Dose Escalation Completed and Monotherapy Expansion Initiated - - Dose Escalation Evaluating IPI-549 in Combination with Opdivo Ongoing; Combination Expansion Expected to Initiate in the Second Half of 2017 - CAMBRIDGE, Mass., Aug. 3, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its second quarter 2017 financial results an... 
Infinity Amends PI3K-Delta,Gamma Agreement with Takeda Oncology
Jul 27, 2017
CAMBRIDGE, Mass., July 27, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), today announced that it has amended its license agreement with Takeda Oncology for IPI-549, Infinity's potentially first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma). Under the amended agreement, Infinity will no longer have an obligation to pay Takeda future royalties on worldwide net sales of selective inhibitors of PI3K-gamma, incl... 
Infinity Announces the Date of Its Second Quarter 2017 Financial Results Conference Call and Webcast
Jul 21, 2017
CAMBRIDGE, Mass., July 21, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Thursday, August 3, 2017, at 4:30 p.m. ET to review its second quarter 2017 financial results and provide an update on the company. A live webcast of the conference call can be accessed in the Investors/Media section of Infinity's website at To participate in the conference call, please dial 1-877-316-5293 (domestic) and 1-631-291-4526 (international) five... 

INFI (Common Stock)

Change: + 0.03 (3.16%)
Intraday High:$1.01
Intraday Low:$0.94
Aug 22, 2017 at 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Annual Report

2016 Annual Report
Data Provided by Thomson Reuters